SCHEMBL989819

SCHEMBL989819

CCCCCCCCCCCCCCCCCCc1cccc2c1C(=O)OC21c2ccc(O)cc2Oc2cc(O)ccc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 8/20 0.52
MAPT P10636 4/20 0.52
MEN1 O00255 3/20 0.52
HTT P42858 3/20 0.52
KMT2A Q03164 3/20 0.52
HPGD P15428 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
CYP2C19 P33261 1/20 0.52
RECQL P46063 1/20 0.52
BLM P54132 1/20 0.52
SMAD3 P84022 1/20 0.52
PRMT1 Q99873 1/20 0.52
ACE2 Q9BYF1 1/20 0.52
ALOX15 P16050 2/20 0.50
ALDH1A1 P00352 2/20 0.50
ALOX12 P18054 2/20 0.50
CYP2C9 P11712 1/20 0.50
BRCA1 P38398 1/20 0.50
HSD17B10 Q99714 1/20 0.50
CYP3A4 P08684 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6738373 1.00 FTO (0.52) FTOMAPTMEN1HTTKMT2A
SCHEMBL622479 0.96 FTO (0.54) FTOMAPTMEN1HTTKMT2A
SCHEMBL16116120 0.89 FTO (0.54) FTOMAPTMEN1HTTKMT2A
SCHEMBL6888031 0.88 FTO (0.41) FTOMAPTMEN1HTTKMT2A
SCHEMBL8196841 0.88 FTO (0.48) FTOMAPTMEN1HTTKMT2A
SCHEMBL3788322 0.88 FTO (0.48) FTOMAPTMEN1HTTKMT2A
SCHEMBL3694702 0.88 FTO (0.51) FTOMAPTMEN1HTTKMT2A
SCHEMBL2314510 0.87 FTO (0.60) FTOMAPTMEN1HTTKMT2A
SCHEMBL4824384 0.87 FTO (0.54) FTOMAPTMEN1HTTKMT2A
SCHEMBL9192235 0.84 FTO (0.49) FTOMAPTMEN1HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6524242-B2 Non-contact method for measuring amount of sebum or oil on substrate in real time using fluorescence dye UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. 2003-02-25 US claimed
US-20030004404-A1 NON-CONTACT METHOD FOR MEASURING AMOUNT OF SEBUM OR OIL ON SUBSTRATE IN REAL TIME USING FLUORESCENCE DYE UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. 2003-01-02 US claimed
CN-109867683-B Triazolyl benzaldehyde fluorescein hydrazide Schiff base and preparation method thereof 齐鲁工业大学 2021-08-10 CN disclosed
CN-112390805-A Benzimidazole benzaldehyde fluorescein hydrazide Schiff base and preparation method thereof 齐鲁工业大学 2021-02-23 CN disclosed
US-10180424-B2 Enhancement solution for enhancing chemiluminescence and method for preparing chemiluminescent solution SHENZHEN MAXCHEMTECH CO., LTD. (CN) 2019-01-15 US disclosed
US-20170016887-A1 ENHANCEMENT SOLUTION FOR ENHANCING CHEMILUMINESCENCE AND METHOD FOR PREPARING CHEMILUMINESCENT SOLUTION SHENZHEN MAXCHEMTECH CO., LTD. (CN) 2017-01-19 US disclosed
CN-104597233-B Liquid and the method for preparing chemical luminescence for liquid is strengthened for enhanced chemiluminescence 深圳市美凯特科技有限公司 2016-09-14 CN disclosed
CN-104597233-A Enhancement solution for chemiluminiscence enhancement and chemiluminescent solution preparation method SHENZHEN MAXCHEMTECH CO LTD 2015-05-06 CN disclosed
US-20130211043-A1 METHOD FOR PREVENTING HIV-1 INFECTION OF CD4+ CELLS CYTODYN, INC. (US) 2013-08-15 US disclosed
US-7935797-B2 Contacting with monoclonal antibody which binds to chemokine receptor; blocks fusion and inhibits activation of inflammatory response PROGENICS PHARMACEUTICALS INC. (US) 2011-05-03 US disclosed
EP-1998812-B1 METHOD TO ASSESS SURFACTANT ADSORPTION ON SKIN UNILEVER PLC (GB) 2011-04-13 EP disclosed
WO-1998056421-A1 METHOD FOR PREVENTING HIV-1 INFECTION OF CD4+ CELLS PROGENICS PHARMACEUTICALS, INC. (US) 1998-12-17 WO disclosed
EP-0847452-A1 FLUORESCENCE RESONANCE ENERGY TRANSFER SCREENING ASSAY FOR THE IDENTIFICATION OF HIV-1 ENVELOPE GLYCOPROTEIN-MEDICATED CELL PROGENICS PHARMACEUTICALS, INC. (US) 1998-06-17 EP disclosed
WO-1997047318-A1 USES OF A CHEMOKINE RECEPTOR FOR INHIBITING HIV-1 INFECTION PROGENICS PHARMACEUTICALS, INC. (US) 1997-12-18 WO disclosed
WO-1997047319-A1 USES OF A CHEMOKINE RECEPTOR FOR INHIBITING HIV-1 INFECTION PROGENICS PHARMACEUTICALS, INC. (US) 1997-12-18 WO disclosed
WO-1997037005-A1 METHOD FOR PREVENTING HIV-1 INFECTION OF CD4+ CELLS PROGENICS PHARMACEUTICALS, INC. (US) 1997-10-09 WO disclosed
WO-1997026009-A1 COMPOUNDS CAPABLE OF INHIBITING HIV-1 INFECTION PROGENICS PHARMACEUTICALS, INC. (US) 1997-07-24 WO disclosed
WO-1996041020-A1 FLUORESCENCE RESONANCE ENERGY TRANSFER SCREENING ASSAY FOR THE IDENTIFICATION OF HIV-1 ENVELOPE GLYCOPROTEIN-MEDICATED CELL PROGENICS PHARMACEUTICALS, INC. (US) 1996-12-19 WO disclosed
EP-0738330-A1 METHODS FOR USING RESONANCE ENERGY TRANSFER-BASED ASSAY OF HIV-1 ENVELOPE CLYCOPROTEIN-MEDIATED MEMBRANE FUSION, AND KITS FOR PRACTICING SAME PROGENICS PHARMACEUTICALS, INC. (US) 1996-10-23 EP disclosed
WO-1995016789-A1 METHODS FOR USING RESONANCE ENERGY TRANSFER-BASED ASSAY OF HIV-1 ENVELOPE CLYCOPROTEIN-MEDIATED MEMBRANE FUSION, AND KITS FOR PRACTICING SAME PROGENICS PHARMACEUTICALS, INC. (US) 1995-06-22 WO disclosed